J. Risvanis

发表

Effects of drinking on thirst and vasopressin in dehydrated elderly men.

C. Johnston, M. Bretherton, D. Casley, 1993, The American journal of physiology.

Myocardial infarction increases ACE2 expression in rat and humans.

P. Macdonald, C. Johnston, M. Cooper, 2005, European heart journal.

Neurohormonal antagonism in heart failure ; beneficial effects of vasopressin V and V receptor blockade and ACE inhibition 1 a 2 *

C. Johnston, J. Risvanis, L. Burrell, 2002 .

Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.

C. Johnston, P. Phillips, J. Risvanis, 1995, Hypertension.

Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.

C. Johnston, P. Phillips, J. Risvanis, 1994, Hypertension.

Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.

C. Johnston, P. Phillips, J. Risvanis, 1998, American journal of physiology. Heart and circulatory physiology.

Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.

C. Johnston, P. Phillips, J. Risvanis, 1998, The American journal of physiology.

Vasopressin V1a and V2 receptor mRNA in deoxycorticosterone acetate-salt hypertension in the rat.

C. Johnston, P. Phillips, J. Risvanis, 1998, Clinical science.

New hormonal blockade strategies in cardiovascular disease.

C. Johnston, J. Risvanis, L. Burrell, 1998, Scandinavian cardiovascular journal. Supplement.

In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.

C. Johnston, J. Risvanis, L. Burrell, 1999, European journal of pharmacology.

Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).

C. Johnston, P. Phillips, J. Risvanis, 1994, Blood pressure.

EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN V1 RECEPTOR ANTAGONIST

C. Johnston, P. Phillips, J. Risvanis, 1993, Clinical and experimental pharmacology & physiology.

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues.

C. Johnston, J. Risvanis, 1997, American journal of hypertension.

Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension.

P. Phillips, J. Risvanis, D. Trinder, 1992, Hypertension.

V1-like [Arg8]vasopressin binding sites occur in rat hepatocyte nuclei.

C. Johnston, P. Phillips, J. Risvanis, 1994, European journal of pharmacology.

Androgen manipulation and vasopressin binding in the rat brain and peripheral organs.

B. Oldfield, J. Risvanis, D. Trinder, 1994, European journal of endocrinology.

Vasopressin V1 and V2 receptors in diabetes mellitus.

M. Cooper, P. Phillips, J. Risvanis, 1994, The American journal of physiology.

Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495.

C. Johnston, J. Risvanis, L. Burrell, 1997, Clinical science.

Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension.

C. Johnston, P. Phillips, J. Risvanis, 1997, Clinical and experimental hypertension.

[3H]desGly-NH2 9-d(CH2)5[D-Ileu2,Ileu4]AVP: An AVP V2 receptor antagonist radioligand

P. Phillips, J. Risvanis, D. Trinder, 1991, Peptides.

Age-dependent regulation of renal vasopressin V(1A) and V₂ receptors in rats with genetic hypertension: implications for the treatment of hypertension.

C. Johnston, J. Risvanis, L. Burrell, 2013, Journal of the American Society of Hypertension : JASH.

Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertension

C. Johnston, J. Risvanis, L. Burrell, 2000, Experimental physiology.

Vasopressin Receptor Expression in the Placenta

J. Risvanis, L. Burrell, K. Moritz, 2003, Biology of reproduction.

Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy

C. Johnston, M. Cooper, W. Burns, 2003, Hypertension.

Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.

C. Johnston, J. Risvanis, L. Burrell, 2002, Cardiovascular research.

Mechanism of progression of renal disease: current hemodynamic concepts.

C. Johnston, I. Tikkanen, J. Risvanis, 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

EFFECTS OF ANTI‐EMETICS ON WATER EXCRETION IN HUMANS

P. Phillips, J. Risvanis, A. Hutchins, 1994, Clinical and Experimental Pharmacology and Physiology.

Epidermal growth factor antagonizes vasopressin in vivo and in vitro.

P. Phillips, J. Risvanis, J. Stephenson, 1994, Kidney international.